TABLE 2.
Pharmacokinetic estimates for ceftriaxone across the study phases
| Phasea | Mean value (SD)b
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Total drug concn data |
Free drug concn data |
|||||||
| AUC0–24 (mg · h/liter) | kel (h−1) | V (liters) | CL (liters/h) | AUC0–24 (mg · h/liter) | kel (h−1) | V (liters) | CL (liters/h) | |
| 1 | 83.6 (13.4) AB | 1.2 (0.4) B | 19.9 (5.9) B | 21.9 (3.1) AB | 68.0 (11.4) AB | 1.3 (0.5) | 23.5 (7.2) | 27.0 (4.1) AB |
| 2 | 65.0 (13.5) C | 1.1 (0.2) C | 26.8 (6.2) C | 28.5 (5.1) C | 51.0 (10.9) C | 1.0 (0.1) | 36.6 (9.4) | 36.3 (6.1) C |
| 3 | 284.4 (40.1) | 0.7 (0.1) | 9.7 (1.1) | 6.4 (1.0) | 88.5 (14.0) | 1.0 (0.3) | 22.5 (4.3) | 20.7 (3.6) |
a
Phase 1, normoalbuminemia; phase 2, hypoalbuminemia; phase 3, albumin replacement.
b
AUC0–24, area under the concentration-time curve during a 24-h period; CL, clearance; kel, elimination rate constant; V, volume of distribution; A, significant difference (P < 0.05) between phases 1 and 2; B, significant difference (P < 0.05) between phases 1 and 3; C, significant difference (P < 0.05) between phases 2 and 3.